Health Partners •••• Medicare

2023 PRIOR AUTHORIZATION REQUEST FORM

Repatha - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

Patient Name:	Prescriber Name:	
Member Number:	Fax: Phone:	
Date of Birth:	Office Contact:	
Line of Business:	NPI: State Lic ID:	
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	
REQUEST FOR EXPEDITED REVIEW: By the life or health of the enrollee or the enrollee.	cking this box and signing below, I certify that applying the 72 hour standard review timeframe may seriously jeopardize 's ability to regain maximum function.	
Drug Name:		
Strength:		
Directions / SIG:		
Diago attach any partinant	dical history including labs and information for this member that may support approval.	
Please attach any pertinent	Please answer the following questions and sign.	
Q1. Is Repatha being pre endocrinologist, or lipido	cribed by or in consultation with an appropriate specialist (cardiologist, ist)?	
☐ Yes	□ No	
Q2. Does the patient have the diagnosis of homozygous familial hypercholesterolemia as defined by one of the following? A.) Genetic confirmation of 2 mutant alleles in the LDL receptor, Apo B- 100 or PCSK9 gene B.) Untreated LDL-C greater than 500 mg/dl C.) Treated LDL-C greater than or equal to 300 mg/dl with cutaneous or tendonous xanthoma before the age of 10 D.) Untreated LDL-C levels consistent with heterozygous familial hypercholesterolemia in both parents		
Must attach documentati	•	
☐ Yes	□No	
Q3. Is the patient 10 yea	of age or older?	
☐ Yes	□ No	
Q4. Is the patient being p	scribed 420 mg once per month?	
Yes	□ No	
_	_	

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Health Partners ••• Medicare

2023 PRIOR AUTHORIZATION REQUEST FORM

Repatha - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:	
Q5. 5. Does the patient of a diagnosis of heteroz defined by one of the following? Please attach do A.) Genetic confirmation B.) Dutch Lipid Network Criteria with a score grea	ocumentation	
□Yes	□ No	
Q6. Is the patient 10 years of age or older?		
☐ Yes	□ No	
Q7. Does the patient have primary hyperlipidemic (ASCVD)? Please attach documentation.	a or clinical atherosclerotic cardiovascular disease	
☐ Yes	□ No	
Q8. Is the patient 18 years of age or older?		
☐ Yes	□ No	
Q9. Has the patient had a prior treatment history with at least one high intensity statin therapy (atorvastatin 40 mg or 80 mg or rosuvastatin 20mg or 40 mg) for at least three continuous months with failure to reach target LDL-C levels?		
□Yes	□No	
Q10. Has the patient experienced statin-associat Must attach documentation.	red side effects?	
☐ Yes	□ No	
Q11. Does the patient have a condition that would be considered a contraindication to statin therapy, including active liver disease, or persistent elevation of serum transaminases?		
☐ Yes	□ No	
Q12. Have either baseline labs or post-treatment	: labs (lipid profile) been attached?	
☐ Yes	□ No	
Q13. Is this a request for a continuation of therap	by?	
☐ Yes	□No	
Q14. Additional Information:		

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Health Partners ••• Medicare

2023 PRIOR AUTHORIZATION REQUEST FORM

Repatha - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:
Q15. Duration: ☐ Initial Request - 6 months ☐ Continuation Request - 12 months ☐ Other:	
Prescriber Signature	Date 2023 Medicare Prior Authorization Reques